Perspective of losigamone in epilepsy treatment

Polish Journal of Pharmacology

Volumn 55, Issue 5, 2003, Pages 675-682

  Kimber Trojnar, Zaneta ^a   Borowicz, Kinga Kornel ^a   Małek, Robert ^a   Sobieszek, Grzegorz ^a   Piskorska, Barbara ^a   Czuczwar, Stanisław J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Antiepileptic drugs; Experimental models of epilepsy; Losigamone; Refractory epilepsy

Indexed keywords

4 AMINOPYRIDINE; ADD 137022; BICUCULLINE; BUTENOLIDE; CARBAMAZEPINE; CYTOCHROME P450 2A6; ETHOSUXIMIDE; FLUNITRAZEPAM; LAMOTRIGINE; LOSIGAMONE; MAGNESIUM ION; NICOTINE; PENTETRAZOLE; PHENYTOIN; PICROTOXIN; TERT BUTYLBICYCLOPHOSPHOROTHIOATE S 35; VALPROIC ACID; FURAN DERIVATIVE;

ATAXIA; CLONIC SEIZURE; CONCENTRATION LOSS; DRUG ANTAGONISM; DRUG DEPENDENCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; ELECTROCUTION; ENANTIOMER; ENTORHINAL CORTEX; EPILEPSY; FATIGUE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HEADACHE; HIPPOCAMPUS; HUMAN; HYPOMAGNESEMIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NAUSEA; NONHUMAN; PREDICTION; RAT; REVIEW; RODENT; SEDATION; SEIZURE; SIDE EFFECT; SPECIES DIFFERENCE; VERTIGO; ANIMAL; DRUG SCREENING;

ANIMALS; DRUG EVALUATION, PRECLINICAL; EPILEPSY; FURANS; HUMANS;

EID: 0346327433     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. + current in pyramidal neurons from rat and cat sensorimotor cortex. J. Neurosci., 1993, 13, 660-673.
2. Azous R., Jensen M.S., Yaari Y.: Ionic basis of spike after-depolarization and burst generation in adult rat hippocampal CA1 pyramidal cells. J. Physiol., 1996, 492, 211-223.
3. Bauer J., Dienel A., Elger C.E., Losigamone Study Group: Losigamone add-on therapy in partial epilepsy: a placebo-controlled study. Acta Neurol. Scand., 2001, 103, 226-230.
4. Bazil C.W., Pedley T.A.: Advances in the medical treatment of epilepsy. Annu. Rev. Med., 1998, 49, 135-162.
5. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., Perucca E.: Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res., 1999, 34, 1-41.
6. Brodie M.J.: Do we need any more new antiepileptic drugs? Epilepsy Res., 2001, 45, 3-6.
7. Browne T.R., Holmes G.L.: Epilepsy. N. Engl. J. Med., 2001, 344, 1145-1151.
8. Chatterjee S.S., Klessing K., Stein U.: AO-33: a new tetronic acid derivative with anticonvulsant properties. 18th Int. Epilepsy Congress (Oct. 17-22, New Delhi), 1989, Abstr. 23.
9. Crill W.E.: Persistent sodium current in mammalian central neurons. Annu. Rev. Physiol., 1996, 58, 349-362.
10. Czuczwar S.J., Borowicz K.K.: Polytherapy in epilepsy: the experimental evidence. Epilepsy Res., 2002, 52, 15-23.
11. Czuczwar S.J., Przesmycki K.: Felbamate, gabapentin and topiramate as adjuvant antiepileptic drugs in experimental models of epilepsy. Pol. J. Pharmacol., 2001, 53, 65-68.
12. Deckers C.L., Czuczwar S.J., Hekster Y.A., Keyser A., Kubova H., Meinardi H., Patsalos P.N., Renier W.O., Van Rijn C.M.: Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia, 2000, 41, 1364-1374.
13. Dienel A., Biber A.: Losigamone: comprehensive summary of safety and tolerability in volunteers. Epilepsia, 1996, 37, Suppl. 4, 63-64.
14. Dimpfel W., Chatterjee S.S., Noldner M., Ticku M.K.: Effects of the anticonvulsant losigamone and its isomers on the GABAA receptor system. Epilepsia, 1995, 36, 983-989.
15. Draguhn A., Jungclaus M., Sokolowa S., Heinemann U.: Losigamone decreases spontaneous synaptic activity in cultured hippocampal neurons. Eur. J. Pharmacol., 1997, 325, 245-251.
16. 0 in the hippocampal slice. Brain Res., 1986, 386, 1-11.
17. Gasior M., Ungard J.T., Witkin J.M.: Preclinical evaluation of newly approved and potential antiepileptic drugs against cocaine-induced seizures. J. Pharmacol. Exp. Ther., 1999, 290, 1148-1156.
18. Gebhardt C., Breustedt J.M., Noldner M., Chatterjee S.S., Heinemann U.: The antiepileptic drug losigamone decreases the persistent Na+ current in rat hippocampal neurons. Brain Res., 2001, 920, 27-31.
19. Heinemann U., Franceschetti S., Hamon B., Konnerth A., Yaari Y.: Effects of anticonvulsants on spontaneous epileptiform activity which develops in the absence of chemical synaptic transmission in hippocampal slices. Brain Res., 1985, 325, 349-352.
20. Jones F.A., Davies J.A.: The anticonvulsant effects of the enantiomers of losigamone. Brit. J. Pharmacol., 1999, 128, 1223-1228.
21. Klessing K., Chatterjee S.S.: Beta-Methoxybutenolide als potentielle Antikonvulsiva: diastereoselektive Synthese und Strukturwirkungsbeziehungen. Int. Symposion: Dreidimensionale Struktur und Wirkung, Schliersee (Oct. 2-4), 1989.
22. Kocki T., Urbańska E.U., Wielosz M., Turski W.A.: Effect of antiepileptic drugs on synthesis of kynurenic acid in the rat cortical slices. Pol. J. Pharmacol., 2003, 55, 1, 115.
23. Kohr G., Heinemann U.: Effects of the tetronic acid derivatives AO33 (losigamone) and AO78 on epileptiform activity and on stimulus-induced calcium concentration changes in rat hippocampal slices. Epilepsy Res., 1990, 7, 49-58.
24. Kohr G., Heinemann U.: Anticonvulsant properties of tetronic acid derivatives on picrotoxin-induced epileptiform activity in rat hippocampal slices. Neurosci. Lett., 1990, 112, 43-47.
25. Kramer G., Wad N., Bredel-Geissler A., Dienel A., Biber A.: Losigamone interactions with antiepileptic drugs in healthy volunteers. Epilepsia, 1996, 37, Suppl. 4, 89.
26. Kwan P., Brodie M.J.: Early identification of refractory epilepsy. N. Engl. J. Med., 2000, 342, 314-319.
27. Lampl I., Schwindt P., Crill W.: Reduction of cortical pyramidal neuron excitability by the action of phenytoin on persistent Na+ current. J. Pharmacol. Exp. Ther., 1998, 284, 228-237.
28. 2+ concentration. Exp. Brain Res., 1993, 96, 230-240.
29. Löscher W, Nolting B.: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices. Epilepsy Res., 1991, 9, 1-10.
30. Löscher W: Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol. Sci., 2002, 23, 113-118.
31. Łuszczki J., Krysa J., Pasztelan I., Czuczwar M., Kiś J., Tarkowski A., Czochra P., Świader M., Czuczwar S.J.: Interactions of lamotrigine with some antiepileptic drugs: an isobolographic analysis. Pol. J. Pharmacol., 2002, 54, 82-84.
32. Magistretti J., Ragsdale D.S., Alonso A.: High conductance sustained single-channel activity responsible for the low-threshold persistent Na(+) current in entorhinal cortex neurons. J. Neurosci., 1999, 19, 7334-7341.
33. McCabe P.H.: New anti-epileptic drugs for the 21st century. Expert Opin. Pharmacother., 2000, 1, 633-674.
34. Noldner M., Chatterjee S.S.: Losigamone. Drugs Future, 1990, 15, 995-996
35. Pelter A., Ayoub M.T., Schultz J., Hansel R., Reinhardt D.: The synthesis of piperolide and related compounds. Tetrahedron Lett., 1979, 20, 1627-1630.
36. Pelter A., Al-Bagati R., Hansel R., Dinter H., Burke B.: The structure and synthesis of fadyenolide, a new butenolide from piper fadyenii. Tetrahedron Lett., 1981, 22, 1545-1548.
37. Peeters P.A.M., Van Lier J.J., Van De Merbel N., Ooserhuis B., Wieling J., Jonkman J.H.G., Klessing K., Biber A.: Pharmacokinetics of [14C]-labelled losigamone and enantiomers after oral administration to healthy subjects. Eur. J. Drug Metab. Pharm., 1998, 23, 45.
38. Regesta G., Tanganelli P.: Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res., 1999, 34, 109-122.
39. Sander J.W.A.S.: Some aspects of prognosis in the epilepsies: a review. Epilepsia, 1993, 34, 1007-1016.
40. Schachtner J.E., Stachel H.D., Chatterjee S.S., Hauer H., Polborn K.: Synthesis and anticonvulsive activity of thiolosigamone. Eur. J. Med. Chem., 1998, 33, 665-669.
41. Schmidt D., Gram L.: Monotherapy versus polytherapy in epilepsy. CNS Drugs, 1995, 3, 194-208.
42. Schmitz D., Gloveli T., Heinemann U.: Effects of losigamone on synaptic potentials and spike frequency habituation in rat entorhinal cortex and hippocampal CA1 neurones. Neurosci. Lett., 1995, 200, 141-143.
43. Segal M.M., Douglas A.F.: Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin. J. Neurophysiol., 1997, 77, 3021-3034.
44. Srinivasan J., Richens A., Davies J.A.: The effect of losigamone (AO-33) on electrical activity and excitatory amino acid release in mouse cortical slices. Brit. J. Pharmacol., 1997, 122, 1490-1494.
45. Stein U., Messing K., Chatterjee S.S.: Losigamone. In: New Antiepileptic Drugs. Eds. Pissani F., Perucca E., Avanzini G., Richens A., Elsevier, Amsterdam, 1991, 129-133.
46. Stein U.: Potential antiepileptic drugs: losigamone. In: Antiepileptic Drugs. Eds. Levy R.H., Mattson R.H., Meldrum B.S., Raven Press, New York, 1995, 1025-1034.
47. Steinhoff B.J., Freudenthaler N., Paulus W.: The influence of established and new antiepileptic drugs on visual perception. 1. A placebo-controlled, double-blind, single-dose study in healthy volunteers. Epilepsy Res., 1997, 29, 35-47.
48. + current in neocortical neurons. Epilepsy Res., 1998, 32, 304-308.
49. + current fractions by the new anticonvulsant topiramate. J. Pharmacol. Exp. Ther., 1999, 288, 960-968.
50. Torchin C.D., McNeilly P.J., Kapetanovic I.M., Strong J.M., Kupferberg H.J.: Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes. Drug Metab. Disposition, 1996, 24, 1002-1008.
51. Torchin C.D., Yonekawa W.D., Kapetanovic I.M., Kupferberg H.J.: Chiral high-performance liquid chromatographic analysis of enantiomers of losigamone, a new candidate antiepileptic drug. J. Chromatogr. B - Bio. Med. Appl., 1999, 724, 101-108.
52. Willmore L.J.: Losigamone. Dr Willmar Schwabe. Curr. Opin. Investig. Drugs, 2001, 2, 1763-1766.
53. Yonekawa W.D., Kapetanovic I.M., Kupferberg H.J.: The effects of anticonvulsant agents on 4-aminopyridine-induced epileptiform activity in rat hippocampus in vitro. Epilepsy Res., 1995, 20, 137-150.
54. Zhang C.L., Chatterjee S.S., Stein U., Heinemann U.: Comparison of the effects of losigamone and its isomers on maximal electroshock induced convulsions in mice and on three different patterns of low magnesium induced epileptiform activity in slices of the rat temporal cortex. Naunyn-Schmied. Arch. Pharmacol., 1992, 345, 85-92.
55. Zhang C.L., Gloveli T., Heinemann U.: Effects of NMDA- and AMPA-receptor antagonists on different forms of epileptiform activity in rat temporal cortex slices. Epilepsia, 1994, 35, Suppl. 5, S68-S73.